Skip to content Skip to footer
Subscribe Now
NEWS

Italfarmaco Collaborates with VeriSIM Life to Develop Novel HDAC-Targeting Therapeutics

Shots: Italfarmaco & VeriSIM Life have entered into a strategic collaboration to discover & develop novel histone deacetylase (HDAC)-targeted therapeutic assets for neuromuscular, fibrotic, & rare diseases As per the deal, VeriSIM Life will receive technology service fees, development, regulatory, & commercial milestone payments, and royalties on future commercial products, with the total potential value…
3 days ago

Read more

NEWS

CSL and Alentis Therapeutics Ink ~$1.55B Global Collaboration to Advance Lixudebart

Shots: CSL & Alentis Therapeutics have entered into an exclusive global collaboration agreement to co-develop & co-promote lixudebart across a range of kidney, liver and other diseases CSL & Alentis will jointly develop & co-promote lixudebart, with CSL paying $355M upfront & Alentis receiving up to $1.2B in commercial milestones. Once commercialised, global profits will…
5 days ago

Read more

Regeneron & Sanofi
NEWS

Regeneron and Sanofi Expand Immunology Alliance in a Deal Valued at ~$8B

Shots: The companies expanded their alliance to add 4 long-acting, Regeneron-invented antibodies targeting IL-13 (REGN20423), IL-4×IL-13 bispecific, IL-4 & IL-4Rα. REGN20423 is in P-I for atopic dermatitis, while the other 3 are expected to enter clinical studies in 2027 As per the expanded agreement, Regeneron & Sanofi will co-develop & co-commercialize the assets, with Regeneron…
October 1, 2026

Read more

NEWS

STADA and Sino Biopharmaceutical Partner to Advance Biosimilar Access   

Shots:  STADA and Sino Biopharmaceutical, through its subsidiary CTTQ, have entered into a strategic biosimilar partnership designed to broaden patient access to biological medicines in key markets  As per the deal, CTTQ will develop, manufacture & supply the biosimilar candidates, while STADA will hold marketing authorizations and exclusive sales & marketing rights in the EU,…
September 28, 2026

Read more

NEWS

Atavistik Bio Inks ~$1.97B Partnership with Roche to Advance Allosteric Small Molecules for CVRM Diseases

Shots: Atavistik Bio has entered into a strategic research collaboration with Roche to discover & develop novel small molecules against multiple targets for cardiovascular, renal, and metabolic (CVRM) diseases, using Atavistik’s AMPS platform As per the deal, Atavistik Bio will be responsible for discovery & research activities for the collaboration targets, with Roche responsible for…
September 25, 2026

Read more

NEWS

Amberstone and Henlius Partner to Develop Conditionally Activated T-Cell Engagers for Solid Tumors

Shots: Amberstone Biosciences has entered into a collaboration & license agreement with Henlius Biotech to advance conditionally activated T-cell engagers for the treatment of solid tumors As per the deal, Amberstone will use its T-MATE platform to generate preclinical candidates against ~2 Henlius-selected targets, while Henlius will lead subsequent research, development, manufacturing & global commercialization…
September 25, 2026

Read more

NEWS

Variant Bio Broadens Discovery Collaboration with Boehringer Ingelheim to Cardiovascular Disease Targets

Shots: Variant Bio has expanded its multi-year research collaboration & license agreement with BI to discover and validate novel cardiovascular disease targets using its Inference platform, building on their existing kidney disease collaboration As per the terms of the expanded agreement, Variant Bio will receive an additional upfront payment & over $250M in potential license…
September 24, 2026

Read more

NEWS

Envisagenics and Boehringer Ingelheim Sign >$1B Cancer Drug Development Deal

Shots: Envisagenics has entered a multi-year research collaboration & option agreement with BI to validate tumor-specific targets for developing first-in-class precision therapies for solid tumors, using Envisagenics’ AI-powered SpliceCore platform  Collaboration builds on targets identified through SpliceCore to validate their potential across ADCs, TCEs & multispecific Abs, with BI having an option to exclusively license…
September 23, 2026

Read more

Load more